126235-09-4

Basic information

• Product Name: 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)-
• CAS NO: 126235-09-4
• Molecular Formula: C15H16N4O2
• Molecular Weight: 284.318
• Mol File: 126235-09-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)-(126235-09-4)
• EPA Substance Registry System: 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)-(126235-09-4)

Safety Data

• Hazardous Substances Data: 126235-09-4(Hazardous Substances Data)

Usage

Molecular Structure

1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)is a heterocyclic organic compound with a purine base structure, two methyl groups at positions 1 and 3, and a phenylethyl group at position 8.

Purine Derivative

This compound belongs to the family of purine derivatives, which are organic compounds that are used as building blocks in the synthesis of nucleic acids and other biological molecules.

Potential Pharmacological Properties

The presence of a phenylethyl group at position 8 gives this compound additional complexity and potential pharmacological properties, making it a valuable candidate for drug discovery and development.

Research and Development Applications

1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-(2-phenylethyl)is used in various research and development applications, particularly in the pharmaceutical industry.

Upstream product

• 5440-00-6 4,5-Diamino-1,3-dimethyluracil 
• 501-52-0 3-Phenylpropionic acid 
• 140-10-3 (E)-3-phenylacrylic acid 

Downstream Products

• 6338-84-7 1,3,7-trimethyl-8-(2-phenylethyl)xanthine 

Relevant articles and documents

1,3,7-Triethyl-substituted xanthines - Possess nanomolar affinity for the adenosine A1 receptor

Adenosine A1 receptors are attracting great interest as drug targets for their role in cognitive deficits. Antagonism of the adenosine A1 receptor may offer therapeutic benefits in complex neurological diseases, such as Alzheimer's and Parkinson's disease. The aim of this study was to discover potential selective adenosine A1 receptor antagonists. Several analogs of 8-(3-phenylpropyl)xanthines (3), 8-(2-phenylethyl)xanthines (4) and 8-(phenoxymethyl)xanthines (5) were synthesized and assessed as antagonists of the adenosine A1 and A2A receptors via radioligand binding assays. The results indicated that the 1,3,7-triethyl-substituted analogs (3d, 4d, and 5d), among each series, displayed the highest affinity for the adenosine A1 receptor with Ki values in the nanomolar range. This ethyl-substitution pattern was previously unknown to enhance adenosine A1 receptor binding affinity. The 1,3,7-triethyl-substituted analogs (3d, 4d, and 5d) behaved as adenosine A1 receptor antagonists in GTP shift assays performed with either rat cortical or whole brain membranes expressing adenosine A1 receptors. Further, in vivo evaluation of 3d showed reversal of adenosine A1 receptor agonist-induced hypolocomotion. In conclusion, the most potent evaluated compound, 8-(3-phenylpropyl)-1,3,7-triethylxanthine (3d), showed both in vitro and in vivo activity, and therefore represent a novel adenosine A1 receptor antagonist that may have potential as a drug candidate for dementia disorders.

Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues

Objectives Caffeine represents a useful scaffold for the design of monoamine oxidase (MAO) type B inhibitors. Specifically, substitution on the C8 position yields structures which are high-potency MAO-B inhibitors. To explore the structure-activity relati